Total Payments
$1.3M
2024 Payments
$156,132
Companies
37
Transactions
607
Medicare Patients
4,755
Medicare Billing
$2.1M
Payment Breakdown by Category
Consulting$755,766 (60.1%)
Travel$275,771 (21.9%)
Other$129,512 (10.3%)
Research$89,019 (7.1%)
Food & Beverage$7,558 (0.6%)
Education$565.76 (0.0%)
Gifts$33.37 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $755,766 | 228 | 60.1% |
| Travel and Lodging | $275,771 | 164 | 21.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $99,761 | 56 | 7.9% |
| Unspecified | $89,019 | 31 | 7.1% |
| Honoraria | $16,460 | 13 | 1.3% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $12,879 | 6 | 1.0% |
| Food and Beverage | $7,558 | 96 | 0.6% |
| Education | $565.76 | 2 | 0.0% |
| Entertainment | $412.46 | 10 | 0.0% |
| Gift | $33.37 | 1 | 0.0% |
Payments by Type
General
$1.2M
576 transactions
Research
$89,019
31 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Optos plc | $375,223 | 182 | $0 (2024) |
| F. Hoffmann-La Roche AG | $224,366 | 96 | $0 (2024) |
| Novartis Pharma AG | $90,284 | 29 | $0 (2022) |
| Regeneron Pharmaceuticals, Inc. | $64,146 | 24 | $0 (2024) |
| Genentech, Inc. | $61,418 | 31 | $0 (2022) |
| Heidelberg Engineering, Inc. | $47,198 | 10 | $0 (2023) |
| Boehringer Ingelheim International GmbH | $43,551 | 18 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $42,752 | 28 | $0 (2021) |
| TOPCON MEDICAL SYSTEMS, INC. | $36,135 | 19 | $0 (2023) |
| Carl Zeiss Meditec, Inc. | $32,858 | 21 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $156,132 | 93 | F. Hoffmann-La Roche AG ($45,989) |
| 2023 | $170,966 | 98 | Optos plc ($57,325) |
| 2022 | $115,928 | 66 | Novartis Pharma AG ($30,419) |
| 2021 | $106,126 | 41 | Novartis Pharma AG ($32,100) |
| 2020 | $142,746 | 69 | Optos Plc ($42,337) |
| 2019 | $186,814 | 72 | F. Hoffmann-La Roche AG ($62,303) |
| 2018 | $257,375 | 88 | OPTOS PLC ($119,758) |
| 2017 | $122,139 | 80 | OPTOS PLC ($56,929) |
All Payment Transactions
607 individual payment records from CMS Open Payments — Page 1 of 25
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Consulting Fee | Cash or cash equivalent | $2,172.00 | General |
| Category: Ophthalmology | ||||||
| 12/18/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | — | Cash or cash equivalent | $3,060.00 | Research |
| Study: A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA • Category: OPHTHALMOLOGY | ||||||
| 12/07/2024 | F. Hoffmann-La Roche AG | — | Travel and Lodging | Cash or cash equivalent | $7,208.01 | General |
| 12/07/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $4,200.00 | General |
| 12/05/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Food and Beverage | In-kind items and services | $74.11 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 12/05/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Education | In-kind items and services | $39.98 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 12/03/2024 | ABBVIE INC. | OZURDEX (Drug) | Consulting Fee | Cash or cash equivalent | $3,075.00 | General |
| Category: EYE CARE | ||||||
| 11/28/2024 | Samsung Bioepis Co., Ltd. | — | Travel and Lodging | Cash or cash equivalent | $78.26 | General |
| 11/27/2024 | Alnylam Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| 11/18/2024 | Optos plc | — | Travel and Lodging | Cash or cash equivalent | $1,134.13 | General |
| 11/18/2024 | Optos plc | — | Food and Beverage | Cash or cash equivalent | $200.00 | General |
| 11/18/2024 | Optos plc | — | Travel and Lodging | Cash or cash equivalent | $74.53 | General |
| 11/18/2024 | Optos plc | — | Travel and Lodging | Cash or cash equivalent | $48.67 | General |
| 11/18/2024 | Optos plc | — | Travel and Lodging | Cash or cash equivalent | $45.84 | General |
| 11/18/2024 | Optos plc | — | Travel and Lodging | Cash or cash equivalent | $36.80 | General |
| 11/18/2024 | Optos plc | — | Travel and Lodging | Cash or cash equivalent | $15.58 | General |
| 11/18/2024 | Optos plc | — | Travel and Lodging | Cash or cash equivalent | $12.53 | General |
| 11/06/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 11/05/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $26.68 | General |
| Category: Ophthalmology | ||||||
| 10/26/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| 10/23/2024 | Tarsus Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| 10/18/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $840.00 | General |
| 10/18/2024 | F. Hoffmann-La Roche AG | — | Food and Beverage | In-kind items and services | $59.85 | General |
| 10/17/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $133.33 | General |
| 10/01/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $840.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | Regeneron Pharmaceuticals, Inc. | $26,347 | 8 |
| A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema | Regeneron Pharmaceuticals, Inc. | $18,113 | 7 |
| Publication support research related | Novartis Pharma AG | $12,922 | 2 |
| LUCENTIS DOSING RETREATMENT | F. Hoffmann-La Roche AG | $11,951 | 2 |
| Lucentis Dosing Retreatment | F. Hoffmann-La Roche AG | $7,342 | 2 |
| VA2 PhIII Yosemite | F. Hoffmann-La Roche AG | $3,236 | 2 |
| GEOGRAPHIC ATROPHY SEGMENTATION USING MULTIMODAL DEEP LEARNING | F. Hoffmann-La Roche AG | $2,214 | 1 |
| SIG (Biomarker data) | F. Hoffmann-La Roche AG | $2,122 | 1 |
| Deep Learning to Predict the Future Growth of Geographic Atrophy from Fundus Autofluorescence | F. Hoffmann-La Roche AG | $1,946 | 1 |
| Geographic Atrophy Segmentation Using Multimodal Deep Learning | F. Hoffmann-La Roche AG | $710.14 | 1 |
| DEEP LEARNING TO PREDICT GEOGRAPHIC ATROPHY AREA AND GROWTH RATE FROM MULTI-MODAL IMAGING | F. Hoffmann-La Roche AG | $687.50 | 1 |
| RELATIONSHIP BETWEEN RETINAL FLUID CHARACTERISTICS AND VISION IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION A POST HOC ANALYSIS OF HARBOR | F. Hoffmann-La Roche AG | $685.56 | 1 |
| Impact of Early Intraretinal Fluid Reduction (IRF) on One-Year Outcomes in Diabetic Macular Edema (DME) | F. Hoffmann-La Roche AG | $436.36 | 1 |
| Impact of Early Intraretinal Fluid Reduction on One-Year Outcomes in DME | F. Hoffmann-La Roche AG | $306.36 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 1,369 | 7,677 | $3.5M | $518,796 |
| 2022 | 8 | 1,318 | 3,773 | $3.5M | $515,869 |
| 2021 | 8 | 1,220 | 3,526 | $3.5M | $534,729 |
| 2020 | 8 | 848 | 2,803 | $3.3M | $528,062 |
Total Patients
4,755
Total Services
17,779
Medicare Billing
$2.1M
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 53 | 304 | $1.3M | $210,914 | 16.7% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 13 | 4,190 | $604,100 | $121,785 | 20.2% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 348 | 950 | $793,250 | $98,066 | 12.4% |
| 92134 | Imaging of retina | Office | 2023 | 337 | 986 | $356,470 | $32,209 | 9.0% |
| 67028 | Injection of drug into eye | Office | 2023 | 64 | 244 | $220,820 | $24,217 | 11.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 114 | 162 | $138,996 | $18,160 | 13.1% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2023 | 298 | 674 | $50,660 | $8,412 | 16.6% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 99 | 123 | $14,335 | $2,436 | 17.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 16 | 16 | $17,360 | $1,720 | 9.9% |
| 92250 | Photography of the retina | Office | 2023 | 27 | 28 | $12,740 | $877.48 | 6.9% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 71 | 448 | $1.9M | $323,215 | 17.3% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 372 | 1,134 | $946,890 | $116,787 | 12.3% |
| 92134 | Imaging of retina | Office | 2022 | 358 | 1,039 | $306,291 | $33,182 | 10.8% |
| 67028 | Injection of drug into eye | Office | 2022 | 75 | 279 | $252,495 | $27,482 | 10.9% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2022 | 253 | 584 | $40,880 | $7,493 | 18.3% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2022 | 155 | 254 | $28,194 | $4,889 | 17.3% |
| 92004 | New patient complete exam of visual system | Office | 2022 | 19 | 19 | $19,095 | $2,317 | 12.1% |
| 92250 | Photography of the retina | Office | 2022 | 15 | 16 | $7,280 | $504.29 | 6.9% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2021 | 60 | 464 | $1.9M | $342,666 | 17.7% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Office | 2021 | 352 | 1,100 | $918,500 | $116,271 | 12.7% |
| 92134 | Diagnostic imaging of retina | Office | 2021 | 349 | 1,023 | $301,678 | $33,588 | 11.1% |
| 67028 | Injection of drug into eye | Office | 2021 | 65 | 276 | $249,780 | $27,254 | 10.9% |
| 92202 | Extended examination of eye with drawing of optic nerve and surrounding area (macula) | Office | 2021 | 208 | 438 | $30,660 | $6,137 | 20.0% |
| 92004 | Eye and medical examination for diagnosis and treatment, new patient, 1 or more visits | Office | 2021 | 39 | 39 | $39,195 | $4,700 | 12.0% |
| 92201 | Extended examination of eye with drawing of retina | Office | 2021 | 134 | 173 | $19,203 | $3,705 | 19.3% |
About Dr. Srinivas Sadda, MD
Dr. Srinivas Sadda, MD is a Ophthalmology healthcare provider based in Pasadena, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1477614790.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Srinivas Sadda, MD has received a total of $1.3M in payments from pharmaceutical and medical device companies, with $156,132 received in 2024. These payments were reported across 607 transactions from 37 companies. The most common payment nature is "Consulting Fee" ($755,766).
As a Medicare-enrolled provider, Sadda has provided services to 4,755 Medicare beneficiaries, totaling 17,779 services with total Medicare billing of $2.1M. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Pasadena, CA
- Active Since 12/12/2006
- Last Updated 01/22/2025
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1477614790
Products in Payments
- Non-Covered Product (Drug) $101,076
- BEOVU (Drug) $72,674
- Lucentis (Biological) $53,586
- Spectralis (Device) $47,198
- P200DTx (Device) $43,098
- EYLEA (Biological) $36,360
- OZURDEX (Drug) $28,220
- CIRRUS HD-OCT (Device) $27,392
- BROLUCIZUMAB (Drug) $24,029
- Jetrea (Drug) $19,579
- OCT-TRITION (Device) $17,227
- RTH258A_BEOVU_OPHTHALMOLOGY (Drug) $16,989
- EYLEA AFLIBERCEPT INJECTION (Biological) $15,102
- Mirante (Device) $14,000
- EYLEA HD (Biological) $12,792
- PANORAMIC OPHTHALMOSCOPE (Device) $11,625
- Vabysmo (Drug) $11,340
- BLZ_BEOVU_OPHTHALMOLOGY (Drug) $10,763
- OCT-MAESTRO (Device) $10,631
- VABYSMO (Drug) $7,332
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Pasadena
Michael Ip, Md, MD
Ophthalmology — Payments: $262,141
Ophthalmology $262,141
Dr. Sahar Bedrood, Md,Phd, MD,PHD
Ophthalmology — Payments: $237,078
Ophthalmology $237,078
Jeffrey Hong, Md, MD
Ophthalmology — Payments: $75,796
Ophthalmology $75,796
Alfredo Sadun, M.d., Ph.d, M.D., PH.D
Ophthalmology — Payments: $27,619
Ophthalmology $27,619
Eugene Chang, Md, MD
Ophthalmology — Payments: $14,875
Ophthalmology $14,875
Dr. Payam Amini, M.d, M.D
Ophthalmology — Payments: $14,341
Ophthalmology $14,341